Franklin Lakes, New Jersey-based BD designed the stent graft to expand treatment options for patients with cirrhosis and complications of portal hypertension. The next-generation, adjustable-diameter device marks the latest advancement for the company in treating complex liver disease.
Liverty TIPS supports individualized patient management, with a 6-10 mm adjustable inner diameter. It also offers the broadest range of covered TIPS stent lengths currently available.
Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation. The stent graft has carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system. BD designed it for placement accuracy, control and ease of use.
“For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical,” said Rima Alameddine, worldwide president of Peripheral Intervention at BD. “With CE Marking of the Liverty™ TIPS Stent Graft, we’re introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long‑term outcomes.”
In addition to CE mark approval, BD announced plans to share data from the ARCH clinical study of Liverty TIPS. Dr. Ziv Haskal will present findings at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12. Haskal serves as the ARCH study’s principal investigator.
Liverty TIPS remains investigational in the U.S.
